Form D · Biotechnology
Magsorbeo Biomedical Corp.
Newark, DE · CIK 0001958753
Offering snapshot reported Dec 21, 2022 · SEC filing
- Reported sold
- $25K Offering amount: $25K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Dec 15, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 21, 2022 | Initial | $25,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-468298
Simple Agreement for Future Equity
Source: Form D, filed Dec 21, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leann Christman | Director |
| Jacob Edick | Director, Executive |
| Joe Messerly | Director |
| Anthony Pizzi | Executive |
| Carolyn Woldring | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
254 Chapman Rd Suite 206
Newark, DE, 19702
Newark, DE, 19702